{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 53,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "thesis_headline",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes ASCO GI 2022 badge and clinical trial references.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/45",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.79
      },
      "kind": "callout",
      "text": "First IO therapy to demonstrate long-term survival in first-line advanced BTC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b35ee88a-ba7d-4a31-8994-da0975501c75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.52,
        "y": 0.62
      },
      "kind": "list",
      "text": "Potential new standard of care in this historically underserved cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62d37221-740f-47b0-804d-b18050f355a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "list",
      "text": "Trial stopped early at an interim analysis due to clear efficacy, with almost 1 in 4 patients alive at two years versus one in 10 on chemotherapy alone",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bfebb91-227c-4ee1-b3cc-1e95ae8e950d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.52,
        "y": 0.73
      },
      "kind": "list",
      "text": "Safety: no AE-related increase in discontinuations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2397a89-a4a9-483d-bb9b-ec3e1e415344",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.15,
        "x": 0.05,
        "y": 0.44
      },
      "kind": "metric",
      "text": "5% to 15%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4ed6457-be26-4fa6-830e-942f81d46e0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.1,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "metric",
      "text": "75%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cef68129-eb0a-4494-8008-f1452e358bb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.15,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "metric",
      "text": "10+ years",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf1244d7-d962-4b33-9118-5f17f95f8ca4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Turkes F, et al. Gastroenterol Res Pract. 2019; 2019:7698786. 2. Vienot A and Neuzillet C. Clin Res Hepatol Gastroenterol. 2020;44:810-824 3. Siegel R, et al. CA Cancer J Clin. 2020; 70: 7-30. and Nakachi K, et al. Japanese Journal of Clinical Oncology. 2018; 48(4): 392-395. and 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. AE = adverse events.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c3b82bf-5b35-4e6d-a43a-1ccfd0e7ea6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.52,
        "y": 0.23
      },
      "kind": "title",
      "text": "TOPAZ-1 has practice-changing potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83b38bb2-c189-4470-b853-269906b38307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "title",
      "text": "Lack of innovation in biliary tract cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c88cae02-3b18-4e42-8417-90c2bfd958f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "TOPAZ-1 has the potential to become the first-ever IO therapy available for first-line, advanced biliary tract cancer patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdf7b24a-f15d-42fb-a97b-22276e9d2f9d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}